

**Table S2.** Univariate COX analysis per tumor type

<b>Parameter</b>	<b>Categories</b>	<b>N patients</b>
<b>Colorectal cancer</b>		
MMR status	Negative vs. Positive	114 vs. 877
MLH1	Negative vs. Positive	63 vs. 909
PMS2	Deficiency vs. Proficiency	69 vs. 910
MSH2	Negative vs. Positive	30 vs. 957
MSH6	Negative vs. Positive	23 vs. 959
MLH1/PMS2 both negative	Deficient vs. Proficient	49 vs. 916
MSH2/MSH6 both negative	Deficient vs. Proficient	13 vs. 971
<b>Endometrial cancer</b>		
MMR status	Negative vs. Positive	80 vs. 87
MLH1	Negative vs. Positive	20 vs. 132
PMS2	Deficiency vs. Proficiency	18 vs. 118
MSH2	Negative vs. Positive	58 vs. 109
MSH6	Negative vs. Positive	4 vs. 155
MLH1/PMS2 both negative	Deficient vs. Proficient	10 vs. 138
MSH2/MSH6 both negative	Deficient vs. Proficient	2 vs. 157

\* Firth's correction was used due to 0 events.

^ Stratified by protocol

## COX

N events	HR <sup>^</sup>	95% CI	Wald's p
27 vs. 252	0.73	0.49-1.09	0.13
14 vs. 262	0.68	0.40-1.17	0.17
16 vs. 261	0.74	0.45-1.23	0.24
6 vs. 271	0.59	0.26-1.32	0.2
6 vs. 270	0.79	0.35-1.78	0.58
10 vs. 264	0.62	0.33-1.17	0.14
2 vs. 274	0.43	0.11-1.74	0.24
12 vs. 30	0.38	0.20-0.76	<b>0.006</b>
6 vs. 33	1.21	0.50-2.91	0.67
5 vs. 35	1.07	0.42-2.74	0.89
6 vs. 36	0.26	0.11-0.61	<b>0.002</b>
1 vs. 41	0.81	0.11-5.89	0.83
4 vs. 35	1.91	0.68-5.39	0.22
0 vs. 42	0.68*	0.04-11.54*	0.79*